Having backed Superluminal Medicines’ series A last year, Eli Lilly has now signed a $1.3 billion pact with the G ...

Evotec’s sweeping reorganization has claimed roughly 600 jobs since last March, 200 more than were originally planned under a ...

Shortly after welcoming a new CEO, robot developer Vicarious Surgical reported that it will be delaying the clinical trials ...

Prelude Therapeutics’ lead asset won’t be making it to the second act. | Prelude Therapeutics’ lead asset won’t be making it ...

Blood oxygen tracking is returning to the Apple Watch after an 18-month hiatus, through a software update effective today.  | ...

A patient has died from kidney injury in a trial of ’ lead antibody-drug conjugate, although the biotech has been advised to ...

Schrödinger is abandoning its CDC7 inhibitor after the therapy was linked to the deaths of two patients in a phase 1 leukemia trial. The biotech had been evaluating the asset, dubbed SGR-2921, in an ...

Sarepta Therapeutics is selling off Arrowhead Pharmaceuticals’ shares to stretch its cash runway, while also inking a share ...

Vedanta Biosciences’ dreams of using live bacteria to treat inflammatory bowel disease (IBD) have been dashed. | Vedanta ...

Generation Bio is shedding 90% of its workforce after the biotech acknowledged it’s unlikely to find the cash to take its ...

After years of being cleared on the European market, Nyxoah’s neuromodulation therapy for obstructive sleep apnea has now ...

As for recent success stories from its biotech portfolio, Hatteras namechecked Kymera Therapeutics. The VC fund contributed ...